Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

CSPC Pharmaceutical’s Megalith Subsidiary Enters $1.77 Billion siRNA Collaboration with AstraZeneca for Novel RNAi Therapeutics

Fineline Cube Jul 3, 2026
Company Deals

Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy

Fineline Cube Jul 2, 2026
Company Deals Digital

Insilico Medicine and Takeda Launch $600M Strategic AI Drug Discovery Collaboration – Pharma.AI Platform to Drive Candidate Identification for High-Potential Therapeutic Targets

Fineline Cube Jul 2, 2026
Company Deals

Nona Biosciences and Lonza Forge Strategic Alliance to Develop Best-in-Class Blood-Brain Barrier Penetration Technology for CNS Therapeutics

Fineline Cube Jul 2, 2026
Company Deals

Ipsen to Acquire Memo Therapeutics for €200M Plus Milestones, Gaining Phase II BK Virus Antibody Potravitug for Transplant Nephropathy

Fineline Cube Jul 2, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Hengrui Pharmaceuticals Secures NMPA Priority Review for Trastuzumab Rezetecan in HER2-Low Breast Cancer, Expanding Third Indication in China

Fineline Cube Jul 3, 2026
Company Drug

Edding Genor’s Trispecific Antibody GB268 Secures NMPA IND Approval for Phase Ib/II Breast Cancer Trial, Targeting TNBC and HR+/HER2- Subtypes

Fineline Cube Jul 3, 2026
Company Legal / IP

Pharmaceutical Giants Face UK Industry Code Breach Allegations, Including Novartis and Pfizer

Fineline Cube Jul 8, 2024

Several multinational pharmaceutical corporations have been reprimanded for violating the UK’s Prescription Medicines Code, a...

Company Drug

Roche’s Tiragolumab Misses Primary Endpoints in NSCLC Trial, Study Halted

Fineline Cube Jul 8, 2024

Roche (SWX: ROG; SWX: RO; OTCMKTS: RHHBY), the Swiss pharmaceutical giant, has announced that a...

Company Drug

Medigene AG Secures Chinese Patent for TCR-T Therapy Targeting NY-ESO-1 and LAGE 1a

Fineline Cube Jul 8, 2024

Medigene AG (ETR: MDG1), a biopharmaceutical company based in Germany, has announced that it has...

Company

MicroPort Scientific Corp’s Subsidiaries Forecast Significant H1 2024 Revenue Growth

Fineline Cube Jul 5, 2024

MicroPort Scientific Corp (HKG: 0853), a leading medical device company, has seen its subsidiaries Shanghai...

Company Deals

Singlera Genomics Secures Over RMB 100 Million in Strategic Financing to Boost R&D and Commercialization

Fineline Cube Jul 5, 2024

Singlera Genomics Inc., a genetic testing and molecular diagnostics company with operations in San Diego,...

Company Drug

Doma Biopharmaceutical’s Bispecific ADC DM001 Receives FDA Clearance for Clinical Trial

Fineline Cube Jul 5, 2024

Doma Biopharmaceutical (Suzhou) Co., Ltd, a biopharmaceutical company based in China, has announced that it...

Company Drug

Jiangsu Hengrui Pharmaceuticals Gets NMPA Green Light for HRS-9813 IPF Clinical Trial

Fineline Cube Jul 5, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced...

Company Drug

Luye Pharma’s Oxycodone/Naloxone Product Receives NMPA Approval for Severe Pain Management

Fineline Cube Jul 5, 2024

Luye Pharma Group (HKG: 2186), a pharmaceutical company based in China, has announced that it...

Company Drug R&D

Semaglutide Use Linked to Rare Eye Condition NAION in New Study

Fineline Cube Jul 5, 2024

A recent study has identified a potential link between the use of GLP-1-targeted diabetes and...

Company Drug

J&J’s Rybrevant Earns First-Line NSCLC Approval in Canada, a Milestone for EGFR Exon 20 Patients

Fineline Cube Jul 5, 2024

Johnson & Johnson (J&J; NYSE: JNJ) has announced that Rybrevant (amivantamab) has received its first...

Company Drug

Sanofi’s RSV Preventative Therapy Beyfortus Launches in China

Fineline Cube Jul 4, 2024

Sanofi (NASDAQ: SNY), a leading French pharmaceutical company, has announced the commercial launch of Beyfortus...

Company Deals

Genertec and CTHG Fund Invest in Neusoft Medical Systems to Boost Medical Imaging

Fineline Cube Jul 4, 2024

China General Technology (Group) Holding Co Ltd, commonly referred to as Genertec, has announced plans...

Company Deals

Guangzhou Pluslife Partners with Gates Foundation to Combat STIs in Low-Income Countries

Fineline Cube Jul 4, 2024

Guangzhou Pluslife Technology Co., Ltd, a specialist in Point-Of-Care Testing (POCT) based in China, has...

Company Deals

United Imaging Healthcare to Launch Financial Leasing Arm with RMB 450 Million Investment

Fineline Cube Jul 4, 2024

United Imaging Healthcare (UIH, SHA: 688271), a leading medical equipment company based in Shanghai, has...

Company Deals

Ascentage Pharma Receives USD 100 Million Option Rights Payment from Takeda

Fineline Cube Jul 4, 2024

Ascentage Pharma (HKG: 6855), a biopharmaceutical company based in China, has announced that it has...

Company Drug

Full-Life Technologies’ ²²⁵Ac-FL-020 Earns FDA Fast-Track Status for mCRPC

Fineline Cube Jul 4, 2024

Full-Life Technologies Ltd, a globally integrated radiotherapeutics company with a presence in Belgium, Germany, and...

Company Drug

HutchMed’s Tazverik for Follicular Lymphoma Accepted for Review by China’s NMPA

Fineline Cube Jul 4, 2024

HutchMed (NASDAQ: HCM), a China-based biopharmaceutical company, has announced that the National Medical Products Administration...

Company Medical Device

Blue Sail Medical’s Fastroad Catheter Earns NMPA Marketing Approval

Fineline Cube Jul 4, 2024

Blue Sail Medical Co., Ltd (SHE: 002382), a medical device company based in China, has...

Company

Philips Appoints Liu Ling as Greater China President Amid Leadership Changes

Fineline Cube Jul 4, 2024

Dutch multinational Philips has appointed Liu Ling as President of Greater China, effective immediately. Liu...

Company Deals

CStone Pharmaceuticals Partners with Hengrui for Promotion of Ayvakit in China

Fineline Cube Jul 4, 2024

CStone Pharmaceuticals (HKG: 2616), a biopharmaceutical company based in China, has announced a licensing agreement...

Posts pagination

1 … 359 360 361 … 690

Recent updates

  • Hengrui Pharmaceuticals Secures NMPA Priority Review for Trastuzumab Rezetecan in HER2-Low Breast Cancer, Expanding Third Indication in China
  • Edding Genor’s Trispecific Antibody GB268 Secures NMPA IND Approval for Phase Ib/II Breast Cancer Trial, Targeting TNBC and HR+/HER2- Subtypes
  • Hengrui Pharmaceuticals Secures NMPA Priority Review for Trastuzumab Rezetecan in HER2-Low Breast Cancer, Expanding Third Indication in China
  • Shandong Boan Biotechnology Secures NMPA Approval for Phase II Trial of BA1106/BA1104 Combination in NSCLC, China’s First Non-IL-2-Blocking Anti-CD25 Antibody
  • CSPC Pharmaceutical’s Megalith Subsidiary Enters $1.77 Billion siRNA Collaboration with AstraZeneca for Novel RNAi Therapeutics
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hengrui Pharmaceuticals Secures NMPA Priority Review for Trastuzumab Rezetecan in HER2-Low Breast Cancer, Expanding Third Indication in China

Company Drug

Edding Genor’s Trispecific Antibody GB268 Secures NMPA IND Approval for Phase Ib/II Breast Cancer Trial, Targeting TNBC and HR+/HER2- Subtypes

Company Drug

Hengrui Pharmaceuticals Secures NMPA Priority Review for Trastuzumab Rezetecan in HER2-Low Breast Cancer, Expanding Third Indication in China

Company Drug

Shandong Boan Biotechnology Secures NMPA Approval for Phase II Trial of BA1106/BA1104 Combination in NSCLC, China’s First Non-IL-2-Blocking Anti-CD25 Antibody

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.